Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Authors

Dennis A. Revicki, United BioSource Corporation
Alfons JM van den Eertwegh, VU University Medical Center
Paul Lorigan, University of Manchester
Celeste Lebbe, APHP Dermatology University
Gerald Linette, Washington University School of Medicine in St. Louis
Christian H. Ottensmeier, Southampton University
Shima Safikhani, United BioSource Corporation
Marianne Messina, Bristol-Myers Squibb
Alex Hoos, Bristol-Myers Squibb
Samuel Wagner, Bristol-Myers Squibb
Srividya Kotapati, Bristol-Myers Squibb

Journal

Health and Quality of Life Outcomes

Publication Date

2012

Volume

10

Issue

1

Inclusive Pages

66

Document Type

Open Access Publication

Rights and Permissions

Revicki et al. Health and Quality of Life Outcomes 2012, 10:66 http://www.hqlo.com/content/10/1/66

Recommended Citation

Revicki, Dennis A.; van den Eertwegh, Alfons JM; Lorigan, Paul; Lebbe, Celeste; Linette, Gerald; Ottensmeier, Christian H.; Safikhani, Shima; Messina, Marianne; Hoos, Alex; Wagner, Samuel; and Kotapati, Srividya, "Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment." Health and Quality of Life Outcomes. 10, 1. 66. (2012).
https://digitalcommons.wustl.edu/open_access_pubs/1177